

To: [redacted]@dsmz.de]; [redacted]@rivm.nl]; [redacted]  
From: [redacted]@dsmz.de]; [redacted]@univ-amu.fr]  
Sent: Thur 3/4/2021 11:23:31 AM  
Subject: RE: Fwd: Nagoya & covid19 manuscript  
Received: Thur 3/4/2021 11:23:31 AM

If we follow the advice of [redacted] and set aside the WHO Journal, then I suggest we stick to our first plan. The article real deserves a broad audience (this is our agreed goal) and a high quality journal.

So I suggest :


The Lancet Infectious Diseases (3000 words) `personal view`. They published on the same subject before [ Peeling et al 2020 ] and might therefore be interested. We can write first to the editors to see whether they are interested beforehand. Second option: the Lancet Global Health Policy.

Science Policy Forum is also good and we have a direct contact there; but the negative is that we will probably have to cut down too much.

Last: I am not in favor of adding new authors to our list of authorships. Everybody who participated actively is rightly acknowledged.

Greetings

[redacted]



dubbel

[redacted]

2 - 6

dubbel